16-Jan-2026
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Glaukos (GKOS)
TipRanks (Thu, 15-Jan 7:54 AM ET)
Wells Fargo Sticks to Its Buy Rating for Glaukos (GKOS)
TipRanks (Thu, 15-Jan 7:51 AM ET)
Analysts Are Bullish on Top Healthcare Stocks: Glaukos (GKOS), Rapid Micro Biosystems (RPID)
TipRanks (Wed, 14-Jan 8:50 AM ET)
Glaukos falls on preliminary Q4 iDose sales
Seeking Alpha News (Wed, 14-Jan 8:47 AM ET)
TipRanks (Wed, 14-Jan 8:07 AM ET)
Piper Sandler Remains a Buy on Glaukos (GKOS)
TipRanks (Wed, 14-Jan 7:06 AM ET)
Why Gelteq Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket
Benzinga (Wed, 14-Jan 5:26 AM ET)
TipRanks (Tue, 13-Jan 6:05 PM ET)
Glaukos Reports Strong Preliminary Q4 and 2025 Sales Growth
TipRanks (Tue, 13-Jan 4:33 PM ET)
Glaukos reports preliminary Q4 results
Seeking Alpha News (Tue, 13-Jan 4:13 PM ET)
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Glaukos trades on the NYSE stock market under the symbol GKOS.
As of January 16, 2026, GKOS stock price climbed to $120.24 with 1,379,018 million shares trading.
GKOS has a beta of 1.37, meaning it tends to be more sensitive to market movements. GKOS has a correlation of 0.20 to the broad based SPY ETF.
GKOS has a market cap of $6.90 billion. This is considered a Mid Cap stock.
Last quarter Glaukos reported $134 million in Revenue and -$.16 earnings per share. This beat revenue expectation by $11 million and exceeded earnings estimates by $.10.
In the last 3 years, GKOS traded as high as $163.71 and as low as $44.26.
The top ETF exchange traded funds that GKOS belongs to (by Net Assets): IJR, VTI, IWM, VB, VBK.
GKOS has underperformed the market in the last year with a return of -23.2%, while SPY returned +18.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in GKOS shares. However, GKOS has outperformed the market in the last 3 month and 2 week periods, returning +40.9% and +8.6%, while SPY returned +5.0% and +1.2%, respectively. This indicates GKOS has been having a stronger performance recently.
GKOS support price is $111.12 and resistance is $117.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GKOS shares will trade within this expected range on the day.